Bold Moves

Win the digital race in pharma

Transform our go-to-market model

Unleash the power of our people

Centers of excellence conduct disease surveillance and real-world vaccine effectiveness studies evaluating vaccine-preventable diseases affecting adults

In January, Pfizer's Vaccines Division announced the launch of its Centers of Excellence Network, a global program of collaborations with academic institutions to conduct real-world epidemiologic research to accurately identify and measure the burden of specific vaccine-preventable diseases and potentially evaluate vaccine effectiveness affecting adults.

With a growing aging population around the world, we’re committed to further understanding how the direct vaccination of adults may potentially prevent certain infectious diseases."

Nanette Cocero

President, Pfizer Vaccines

Pfizer Vaccines has designated the University of Louisville as its first Center of Excellence and is planning to establish a few additional centers for epidemiological research strategically located around the world in coming years.

“With strategically-located research centers, we anticipate being able to better define and understand the global disease burden in adults and vaccine effectiveness. This will help provide robust evidence to the national policymakers and health officials who develop recommendations for the use of vaccines in immunization programs worldwide,” said Luis Jodar, Chief Medical and Scientific Affairs Officer, Pfizer Vaccines.


Streptococcus pneumoniae remains a significant cause of disease and deaths globally for adults with an estimated 500,000 deaths a year.1

On January 23, Pfizer announced the University of Louisville as its first Global Center of Excellence. (l. to r.) Luis Jodar, Chief Medical and Scientific Affairs Officer, Pfizer Vaccines; Neeli Bendapudi, President, University of Louisville; Nanette Cocero, President, Pfizer Vaccines; and Julio Ramirez, Chief of Infectious Diseases and Center Director, University of Louisville


1Pfizer R&D Day transcript, page 25,

Discover more

Advances for a Potential First-in-Class Chronic OA Pain Treatment

Advancing Breakthroughs for Patients With NASH

Eucrisa, Now Starring Jessica Simpson

Working for Patients with Alopecia Areata

Advancing a Potential Breakthrough for Moderate to Severe Atopic Dermatitis

A Potentially Practice-Changing Approval in Advanced Urothelial Cancer

Addressing an Unmet Need for Certain Patients With BRAF-Mutant mCRC

Learning From Early Breast Cancer Studies to Drive Oncology Research Forward

Cancer Doesn’t Wait: Supporting Screenings During COVID-19

Positive Phase 1/2 Data at One Year for Hemophilia A Gene Therapy

Investigational Gene Therapy for Duchenne Muscular Dystrophy Achieves Exciting Milestones in 2020

Pfizer Vaccines Pipeline Includes Six Late-Stage Candidates

Pfizer Vaccines Launches​​​​​​​ Global Centers of Excellence Network

Progressing Maternal Vaccination Against Respiratory Syncytial Virus

Pfizer Pledges $100 Million Into New AMR Industry Fund

Partnering with Wellcome to Combat AMR in Sub-Saharan Africa

Expanding Access in China Through Health Insurance Innovation

Pfizer Invests in Biotechnology Innovation through the Pfizer Breakthrough Growth Initiative

Hospital Donations for COVID-19 Response

Pfizer Partners with BioNTech to Advance & Supply COVID-19 Vaccine​​​​​​​

Delivering on the Promise of Biosimilars

Driving Diversity in Our Research and Development​​​​​​​

Site Feature: Puurs, Belgium 

PGS Ingenuity Solves COVID-19 Cold Chain Storage Challenge​​​​​​​

Pfizer and Gilead Sciences Agree to Manufacture and Supply Remdesivir​​​​​​​

Key Medicine Supply and Public Policy During COVID-19

Pfizer Stands with Science

Five-Point Plan for Unprecedented Collaboration

COVID-19 Updates

Read the latest information about Pfizer’s COVID-19 vaccine on



Join the Conversation

Additional Information

Useful Links

The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

Copyright © 2020-2021 Pfizer Inc.
All rights reserved

Explore our stories